Liver via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase[4]
Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder.[5] Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine.[6] It is taken by mouth.[5]
Common side effects include high blood pressure, headaches, and urinary tract infections.[5] Other significant side effects include urinary retention, irregular heart rate, and angioedema.[5][7] It works by activating the β3 adrenergic receptor in the bladder, resulting in its relaxation.[5][7]
Mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder. Mirabegron was approved for medical use in the United States and in the European Union in 2012.[8][9][3] In 2021, it was the 200th most commonly prescribed medication in the United States, with more than 2million prescriptions.[10][11] It is available as a generic medication.[12]
In the United Kingdom it is less preferred to antimuscarinic medication such as oxybutynin.[7]
^Cite error: The named reference EMC was invoked but never defined (see the help page).
^Cite error: The named reference DM was invoked but never defined (see the help page).
^ abcdeCite error: The named reference MSR was invoked but never defined (see the help page).
^ abcde"Mirabegron Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 18 March 2019.
^"[93] Are claims for newer drugs for overactive bladder warranted?". Therapeutics Initiative. 22 April 2015. Retrieved 17 March 2019.
^ abcBritish national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 763. ISBN 9780857113382.
^"Drug Approval Package: Myrbetriq (mirabegron) Extended Release Tablets NDA #202611". U.S. Food and Drug Administration (FDA). 10 August 2012. Retrieved 28 April 2020.
^Sacco E, Bientinesi R, Tienforti D, Racioppi M, Gulino G, D'Agostino D, et al. (April 2014). "Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence". Expert Opinion on Drug Discovery. 9 (4): 433–448. doi:10.1517/17460441.2014.892923. PMID 24559030. S2CID 26424400.
^"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
^"Mirabegron - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
^"2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits are similar to antimuscarinic...
(DDI). Here vibegron differs from the previous overactive bladder drug mirabegron, which was known to be associated in various drug–drug interactions by...
has developed the first commercially available β3 adrenergic receptor, mirabegron, which is now licensed in Japan and the U.S. exclusively for treatment...
has been linked to dementia. β3 adrenergic receptor agonists (e.g., mirabegron, vibegron) may be used, as well. Patients taking oxybutynin and other...
Global Information
